Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 26, 2025
Product Development
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report
Plus:
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | Oct 31, 2023
Data Byte
Nine PDUFA dates on FDA’s November roster
Decisions include the first vaccine for Chikungunya and three new cancer therapies
BioCentury | May 26, 2023
Finance
May 25 Quick Takes: VarmX is latest biotech to extend series B
Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and more
BioCentury | Jan 23, 2023
Deals
Hutchmed picks Takeda as fruquintinib partner, adding global reach
Selective VEGFR inhibitor improved survival in multi-regional study; regulatory submission started in U.S., other markets to follow
BioCentury | Mar 31, 2021
Regulation
March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor
The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally
BioCentury | Jun 4, 2020
Product Development
June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more
BioCentury | Feb 11, 2020
Product Development
Exelixis eyeing 2021 combo submission in prostate cancer following new readout
BioCentury | Sep 14, 2019
Product Development
Success in lung cancer niches will hinge on access to next-gen sequencing
New targeted RET, cMET and KRAS therapies are crushing SOC, but uptake could come down to NGS availability
BioCentury | Aug 7, 2019
Clinical News
Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea
Items per page:
1 - 10 of 90